Forbes shares that the first attempt for Sanofi Aventis, a bid of $18.5 billion, was rejected by Genzyme. Genzyme believes that the company should be valued at a much higher price. The bid from Sanofi Aventis has been expected. Genzyme is facing a few manufacturing issues when inspectors found particles of trash and other particles in the medication manufactured at several plants. Stock prices of Genzyme, however, continue to rise today, showing that investors believe that Sanofi Aventis will come back with a higher bid.
|
Share this article with your social network, just click below to share now!
|
|
|
photo credit: @KimTweetsDC For over 20 years we have been working hard on delivering you with first-hand insights into one of the mo...
Last month we blogged about five women to watch in Boston biotech and got an incredible response. In a country where less than five percent...
No comments :
Post a Comment